Options de traitement systémique, Centre de Preuves en Dermatologie

Guidelines atopic dermatitis Updated on Jul 25

Responsibility

The information provided by this website comes from sources deemed reliable. However, the Société Française de Dermatologie recommends that the user ensure the validity of this information. Some may prove to be erroneous or be subject to typos or display errors.

The use of this data is under the sole responsibility of the user. The Société Française de Dermatologie cannot be blamed for a misinterpretation of the data provided by the site, or in the event of erroneous information. This decision tree and all the contents of this site have been developed in the context of updated data from science according to the HAS methodology, expert opinions and reviewers of the various documents and in the context of the French healthcare system.

I have read and accept the general conditions of use of this website

Back to decision-making tree Print last updated on 09/02/2026

Biotherapies

Tralokinumab: in adult patients and adolescents from 12 years of age

Tralokinumab is a high-affinity human IgG4 monoclonal antibody that neutralizes IL-13. It has Marketing Authorization (MA) and reimbursement for the treatment of moderate-to-severe AD in adults and adolescents from 12 years of age.

Recommended dose:

300 mg every 2 weeks after a loading dose of 600 mg at treatment initiation. Administration every 4 weeks may be considered by the prescriber for patients who have no or very few lesions after 16 weeks of treatment.

Well tolerated, common adverse events (AEs): conjunctivitis...

Concomitant use of emollients, TCS, TCIs, and phototherapy is possible.

➜ Abrocitinib

Back to decision-making tree Print

Was this article helpful to you?
Your opinion counts!

This notice will not be published on this site, but only sent to the publication management. Your email will only be used to reply to you if we deem it necessary. No response will be sent to any request for medical advice via this form.